Stereotactic Radiotherapy in the Treatment of Lung Metastases from Bone and Soft-tissue Sarcomas

被引：0

作者：

Frakulli, Rezarta ^{[1
]}

Salvi, Fabrizio ^{[2
]}

Balestrini, Damiano ^{[2
]}

Parisi, Alessandro ^{[2
]}

Palombarini, Marcella ^{[3
]}

Cammelli, Silvia ^{[1
]}

Rocca, Michele ^{[4
]}

Salone, Mariacristina ^{[4
]}

Longhi, Alessandra ^{[5
]}

Ferrari, Stefano ^{[5
]}

Morganti, Alessio G. ^{[1
]}

Frezza, Giovanni ^{[2
]}

机构：

[1] Univ Bologna, Dept Expt Diagnost & Specialty Med, Radiat Oncol Ctr, I-40138 Bologna, Italy

[2] Bellaria Hosp, Radiat Oncol Unit, Bologna, Italy

[3] Bellaria Hosp, Med Phys Unit, Bologna, Italy

[4] Rizzoli Orthopaed Inst, Gen & Thorac Surg, Bologna, Italy

[5] Rizzoli Orthopaed Inst, Dept Oncol, Bologna, Italy

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 10期

关键词：

SBRT; sarcoma; lung metastases; PULMONARY METASTASES; SBRT;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The purpose of this study was to evaluate local control and toxicity in a group of patients treated with stereotactic body radiotherapy (SBRT) for lung metastases (LM) from bone and soft tissue sarcomas. Patients and Methods: From October 2010 to July 2014, patients with LM from sarcomas not suitable for surgery were treated with daily cone-beam computed tomography-guided SBRT. The dose administered ranged from 30 to 60 Gy in 3-8 fractions. Acute and late toxicity were scored according to Common Terminology Criteria for Adverse Events version 4.0. Results: A total of 24 patients with 68 LM from sarcomas were treated with SBRT. The median follow-up after SBRT was 17 months (range=11-51 months). Two-year actuarial lesion local control and overall survival were 85.9% and 66.4%, respectively. No G3 or greater acute and late toxicities were observed. Conclusion: SBRT is a safe and effective treatment for LM from sarcoma and might be used as an alternative option in patients unfit for surgery.

引用

页码：5581 / 5586

页数：6

共 27 条

[1] Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) for Treatment of Pulmonary Metastases from Sarcoma: A Potential Alternative to Metastatectomy [J].

Baumann, B. C. ;

Kolker, J. D. ;

Levin, W. P. ;

Nagda, S. N. ;

Weber, K. L. ;

Staddon, A. ;

Hahn, S. M. ;

Glatstein, E. J. ;

Simone, C. B. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 :S119-S120

[2] The Tumor Radiobiology of SRS and SBRT: Are More Than the 5 Rs Involved? [J].

Brown, J. Martin ;

Carlson, David J. ;

Brenner, David J. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02) :254-262

[3]

Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO

[4]

2-3

[5] STEREOTACTIC BODY RADIOTHERAPY FOR PULMONARY METASTASES FROM SOFT-TISSUE SARCOMAS: EXCELLENT LOCAL LESION CONTROL AND IMPROVED PATIENT SURVIVAL [J].

Dhakal, Sughosh ;

Corbin, Kimberly S. ;

Milano, Michael T. ;

Philip, Abraham ;

Sahasrabudhe, Deepak ;

Jones, Carolyn ;

Constine, Louis S. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (02) :940-945

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7]

Fiorentino Fiorentino F F, 2012, BMJ OPEN, P2

[8] THE LINEAR-QUADRATIC FORMULA AND PROGRESS IN FRACTIONATED RADIOTHERAPY [J].

FOWLER, JF .

BRITISH JOURNAL OF RADIOLOGY, 1989, 62 (740) :679-694

[9]

Grimm Jimm, 2011, J Appl Clin Med Phys, V12, P3368

[10]

Gunderson L.L., 2007, Clinical radiation oncology, V2nd

← 1 2 3 →